

REMARKS

The present paper presents an amendment to the claims. Claims 83-89 were pending and under consideration. In this amendment, claims 83-86 are amended, and claims 87-89 are cancelled. Thus, following entry of the present amendment, claims 83-86 are pending and under consideration.

Applicant acknowledges the Examiner's withdrawal of the rejection under 35 U.S.C. § 102(a) and kindly thanks the Examiner for the same.

I. The Amendments to the Claims

In the present paper, claims 83-86 is amended, and claims 87-89 are cancelled. The amendments to claims 83-86 are fully supported by the application as filed, and therefore present no new matter.

Support for the amendments to claim 83 may be found, for example, in the specification at page 95, line 22 to page 96, line 27 and at page 86, lines 5-26. Support for the amendments to claim 84 may be found, for example, in the specification at page 95, line 22 to page 96, line 27. Support for the amendments to claim 85 may be found, for example, in the specification at page 95, line 22 to page 96, line 27. Support for the amendments to claim 86 may be found, for example, in the specification at page 86, lines 5-26.

The foregoing demonstrates that the amendments to the claims are fully supported by the application as filed and thus present no new matter. Entry of the amendments to the claims is therefore respectfully requested under 37 C.F.R. § 1.111.

II. The Rejection of Claims 83-89 as Failing to Comply with the Enablement Requirement Should Be Withdrawn

Claims 83-89 stand rejected under 35 U.S.C § 112, first paragraph, as allegedly failing to comply with the enablement requirement. In particular, the PTO alleges that the claims are rejected on three grounds: (1) the disclosure fails to provide adequate guidance pertaining to the genotypic/phenotypic properties of other RTs as it pertains to NNRTI increased/decreased susceptibility; (2) the disclosure fails to provide sufficient guidance pertaining to the presence of the claimed mutations in the human immunodeficiency virus

type 2 (HIV-2); and (3) the claims are broadly directed toward a large genus of variants, which are not supported by the disclosure.

Applicant has amended claims 83-86 as suggested by the Examiner. Applicant believes that the objection is moot in view of the amendments to the claims and respectfully request its withdrawal.

CONCLUSION

Applicant believes that this application is in condition for allowance. The Examiner is respectfully requested to call the undersigned attorney at (650) 739-3949, if a telephone call could help resolve any outstanding items.

Date: April 28, 2008

Respectfully submitted,



David C. Pauling

56,056
(Reg. No.)

For: Nikolaos C. George (Reg. No.
39,201)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939